In particular, in malignant melanoma PDEs, we observed the movement of CD8 + cytotoxic T lymphocytes in response to the anti-PD1 antibody Nivolumab50, and pembrolizumab-induced death in endometrial cancer PDEs21. The gene discussed is CD8A; the disease is melanoma.